The company has announced the appointments of Patrik Renblad as Vice President Finance and Lise Agersted as Director of Operational R&D.
“We are happy to welcome both Patrik and Lise to the SynAct team,” says SynAct’s CEO Jeppe Øvlesen. “Both are important additions as SynAct pushes forward on its bold strategy to become the leading company in leveraging the melanocortin system to resolve severe inflammation.”
Renblad joins SynAct after a decade in various financial roles at LEO Pharma A/S, where he was most recently Finance Director, R&D, leading the R&D Business Finance Organization and was a member of the LEO Pharma Finance and R&D Leadership teams. Prior to LEO Pharma, Renblad worked nine years at AstraZeneca R&D in Lund, Sweden.
Renblad received his Master of Science in Business Administration and Economics – International Business Program (German) from Lund University, Sweden, in 1996.
Agersted starts at SynAct after three years as an independent consultant for biotech and technology startups. Prior to this, Agersted worked at Novo Nordisk for 8 years and held both scientific and project management roles, recently as Senior CMC Project Management.
Agersted received her Master of Pharmacy from Copenhagen University, Denmark, in 2007, and an MBA in innovation and technology management from École des Ponts business school, Paris, in 2020.